To determine the effect of PROKR2 antagonists on the preeclampsia feature in STOX1 mice, a first group of pregnant mice (crossed with a transgenic male TgSTOX42) was treated with PKRA at three time points of gestation, 7.5, 10.5 and 13.5 dpc whilst a second group was treated with the vehicle at the three time points and considered as the control for the PKRA treatment. The gene discussed is PROKR2; the disease is preeclampsia.